Zicronapine is an antipsychotic medication with a strong pro-cognitive effect in animal models and the potential to treat a number of neurological and psychiatric diseases. Zicronapine has potent antagonistic effects at dopamine D1/D2, and serotonin 5-HT2A receptors.
[1] Lopez De Diego, Heidi. et al. Succinate and malonate salts of trans-4-(1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and their preparation, pharmaceutical compositions, and use as medicaments, particularly as antipsychotics. WO2005016900A1
[2] Lundbeck H. A/S. The clinical phase III programme commenced on zicronapine. 20 Jan 2011.
[3] Lundbeck H, A/S. Zicronapine shows significant positive data in clinical phase II in the treatment of patients with schizophrenia –planning for continued clinical work. Press release No. 392 18 December 2009.
